ATE508185T1 - Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus - Google Patents

Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus

Info

Publication number
ATE508185T1
ATE508185T1 AT05795050T AT05795050T ATE508185T1 AT E508185 T1 ATE508185 T1 AT E508185T1 AT 05795050 T AT05795050 T AT 05795050T AT 05795050 T AT05795050 T AT 05795050T AT E508185 T1 ATE508185 T1 AT E508185T1
Authority
AT
Austria
Prior art keywords
virosome
virus
hepatitis
antigens
provides
Prior art date
Application number
AT05795050T
Other languages
English (en)
Inventor
Christian Moser
Giovanna Assero
Epifanio Fichera
Dario Ventura
Laurence Lempereur
Diana Felnerova
Original Assignee
Crucell Switzerland Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Switzerland Ag filed Critical Crucell Switzerland Ag
Application granted granted Critical
Publication of ATE508185T1 publication Critical patent/ATE508185T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05795050T 2004-10-27 2005-10-20 Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus ATE508185T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04025573A EP1652914A1 (de) 2004-10-27 2004-10-27 Virosom Partikel, Influenzavirus und Hepatitis B Virus Antigenen enthaltend
PCT/EP2005/011297 WO2006045532A2 (en) 2004-10-27 2005-10-20 Virosome particles comprising antigens from influenza virus and hepatitis b virus

Publications (1)

Publication Number Publication Date
ATE508185T1 true ATE508185T1 (de) 2011-05-15

Family

ID=34927140

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05795050T ATE508185T1 (de) 2004-10-27 2005-10-20 Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus

Country Status (12)

Country Link
EP (1) EP1652914A1 (de)
JP (1) JP4870085B2 (de)
KR (1) KR101290475B1 (de)
CN (1) CN101048498B (de)
AT (1) ATE508185T1 (de)
AU (1) AU2005298950B2 (de)
CA (1) CA2585309C (de)
DE (1) DE602005027872D1 (de)
DK (1) DK1802746T3 (de)
ES (1) ES2365738T3 (de)
NZ (1) NZ554498A (de)
WO (1) WO2006045532A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697088B2 (en) * 2007-05-25 2014-04-15 Novavax, Inc. VLPs derived from cells that do not express a viral matrix or core protein
EP2014279A1 (de) * 2007-06-22 2009-01-14 Pevion Biotech AG Virosomen enthaltend Haemagglutinin, das von über Zelllinien hergestellten Influenza-Viren stammt, Zusammensetzungen, Herstellungsverfahren, Verwendung davon
US20110111459A1 (en) * 2008-04-18 2011-05-12 The General Hospital Corporation Compositions and methods for nucleic acid delivery
EA016866B1 (ru) * 2011-06-06 2012-08-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Вакцина для специфической профилактики гриппа
NZ730357A (en) * 2014-09-12 2021-12-24 Bestewil Holding Bv Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
US11020470B2 (en) 2015-04-13 2021-06-01 The Regents Of The University Of Michigan Virus-like particles
CA3046778A1 (en) * 2016-10-31 2018-05-03 Georgia State University Research Foundation, Inc. A virus like particle of hepatitis b virus pre-s protein
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879685A (en) * 1991-05-08 1999-03-09 Schweiz, Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
JPH1171303A (ja) * 1997-08-27 1999-03-16 Rikagaku Kenkyusho Ｂ型肝炎ワクチン
US20030180351A1 (en) * 1998-11-06 2003-09-25 Reinhard Gluck Pharmaceutically active composition and dispensing device
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
BR0316402A (pt) * 2002-11-21 2006-02-21 Pevion Biotech Ltd vesìcula fusogênica, métodos para preparar uma vesìcula fusogênica encapsulante, e para encapsular pelo menos uma substáncia terapêutica ou imunologicamente ativa em uma vesìcula fusogênica, uso de uma vesìcula fusogênica, e, formulação farmacêutica

Also Published As

Publication number Publication date
KR20070095881A (ko) 2007-10-01
WO2006045532A2 (en) 2006-05-04
CA2585309C (en) 2016-09-06
DK1802746T3 (da) 2011-08-15
AU2005298950A1 (en) 2006-05-04
CA2585309A1 (en) 2006-05-04
WO2006045532A3 (en) 2006-08-03
EP1652914A1 (de) 2006-05-03
CN101048498A (zh) 2007-10-03
ES2365738T3 (es) 2011-10-10
JP2008517961A (ja) 2008-05-29
CN101048498B (zh) 2013-02-13
AU2005298950B2 (en) 2010-12-16
DE602005027872D1 (de) 2011-06-16
KR101290475B1 (ko) 2013-07-29
JP4870085B2 (ja) 2012-02-08
NZ554498A (en) 2009-11-27

Similar Documents

Publication Publication Date Title
ATE508185T1 (de) Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus
WO2009050390A3 (fr) Procede de production du virus de la grippe
WO2004080403A3 (en) Influenza virus vaccine
ATE538810T1 (de) Funktionale influenza-virus-ähnliche teilchen (vlps)
DE60139026D1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
MY147379A (en) Chimeric viruses presenting non-native surface proteins and uses thereof
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
DE122011100054I1 (de) Influenza vakzinzusammensetzungen zur intradermaler verabreichung.
NZ587108A (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CN105263516A (zh) 流感病毒疫苗及其用途
DE60226911D1 (de) Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
WO2007047831A3 (en) Functional influenza virus like particles (vlps)
ECSP045300A (es) Antígenos virales
HK1125674A1 (en) Rescue of influenza virus
EA201000076A1 (ru) Новые конструкты для экспрессии вируса гриппа
CY1108789T1 (el) Καθαρισμος αντιγονων hbv για χρηση σε εμβολια
IL203869A (en) Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method
ATE547116T1 (de) Kombinationsimpfstoff
WO2005014778A3 (en) Dna vaccine expressing ha1 of equine-2 influenza virus
WO2007008093A3 (en) A method of manufacturing a recombinant vaccine against viral rabbit haemorrhagic disease, the vaccine, the application of a recombinant antigen in the manufacture of the vaccine
WO2006078272A3 (en) Rhabdoviral n-fusion proteins as carrier for foreign antigens
EA200870361A1 (ru) Интраназальное или ингаляционное введение виросом
HUP0402548A2 (hu) Madárembrió-részecskékből álló biomassza vírusantigének előállítására
CY1116497T1 (el) Λειτουργικα ιομορφα σωματιδια γριπης (vlps)
MX361884B (es) Vacuna inactivada acuosa para la prevencion de influenza aviar.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1802746

Country of ref document: EP